Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

258 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Holstein A, et al. Expert Opin Drug Saf. 2010 Sep;9(5):675-81. doi: 10.1517/14740338.2010.492777. Expert Opin Drug Saf. 2010. PMID: 20553106

Severe hypoglycemia was defined as a symptomatic event requiring treatment with intravenous glucose and was confirmed by a blood glucose measurement of < 50 mg/dl. ...Two-thirds of all subjects lived independently at home whereas a third were cared for by

Severe hypoglycemia was defined as a symptomatic event requiring treatment with intravenous glucose and was confirmed by a blo …
Insulinoma as rare cause of severe post-partum hypoglycemia.
Holstein A, Morgenstern T, Dienst H, Hiller W. Holstein A, et al. J Obstet Gynaecol Res. 2015 Nov;41(11):1848-50. doi: 10.1111/jog.12785. Epub 2015 Sep 24. J Obstet Gynaecol Res. 2015. PMID: 26399682
Post-partum hypoglycemia in non-diabetic women is a rare condition. We report the exceptional case of a 38-year-old obese woman who experienced recurrent neuroglycopenia 3 weeks after delivery. ...In conclusion, insulinoma is a very rare, nonetheless importan …
Post-partum hypoglycemia in non-diabetic women is a rare condition. We report the exceptional case of a 38-year-old obese woma …
Oral antidiabetic agents: how much kidney disease can we tolerate?
Mayer C, Holstein A, Stumvoll M. Mayer C, et al. Among authors: holstein a. Expert Rev Endocrinol Metab. 2007 Jul;2(4):469-475. doi: 10.1586/17446651.2.4.469. Expert Rev Endocrinol Metab. 2007. PMID: 30290417
Type 2 diabetes mellitus and chronic kidney disease in mild and moderate stages is a common and underestimated comorbidity with relevant therapeutic consequences. ...Chronic kidney disease is a very common reason to withhold or discontinue an oral antidiabetic thera …
Type 2 diabetes mellitus and chronic kidney disease in mild and moderate stages is a common and underestimated comorbidity with relev …
Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature.
Holstein A, Stege H, Kovacs P. Holstein A, et al. Expert Opin Drug Saf. 2010 Mar;9(2):225-31. doi: 10.1517/14740330903496402. Expert Opin Drug Saf. 2010. PMID: 20001763 Review.
A new case of lipoatrophy associated with the use of glargine is presented. WHAT THE READER WILL GAIN: Readers will gain insight into: i) pathogenesis of lipoatrophy associated with the use of insulin analogues and ii) clinical features of lipoatrophy. ...
A new case of lipoatrophy associated with the use of glargine is presented. WHAT THE READER WILL GAIN: Readers will gain insight into
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions.
Holstein A, Beil W. Holstein A, et al. Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):225-41. doi: 10.1517/17425250902806424. Expert Opin Drug Metab Toxicol. 2009. PMID: 19331589 Review.
METHODS: A PubMed literature search was performed to select the most recent and relevant publications examining OAD metabolism and the effects of concomitant use of OADs. ...As metformin is cardiovascular protective and is not metabolised through the hepatic cytochrome P45 …
METHODS: A PubMed literature search was performed to select the most recent and relevant publications examining OAD metabolism and th …
Clinical implications of hepatogenous diabetes in liver cirrhosis.
Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Holstein A, et al. J Gastroenterol Hepatol. 2002 Jun;17(6):677-81. doi: 10.1046/j.1440-1746.2002.02755.x. J Gastroenterol Hepatol. 2002. PMID: 12100613
The examination included a history, determination of basal C-peptide and glycosylated hemoglobin (HbA(1c)) and, in some cases, a 3 h oral glucose tolerance test with 100 g glucose. ...Sixteen percent of patients with hepatogenous diabetes had a family history …
The examination included a history, determination of basal C-peptide and glycosylated hemoglobin (HbA(1c)) and, in some cases, a
The Glu23Lys polymorphism in KCNJ11 and impaired hypoglycaemia awareness in patients with type 1 diabetes.
Holstein A, Plaschke A, Stumvoll M, Kovacs P. Holstein A, et al. J Hum Genet. 2005;50(10):530-533. doi: 10.1007/s10038-005-0288-y. Epub 2005 Sep 2. J Hum Genet. 2005. PMID: 16142506
Genotyping of the Glu23Lys in a cohort of T1D subjects was done using the TaqMan allelic discrimination assay (frequency of the Lys-allele = 0.35; P = 0.57 for Hardy-Weinberg equilibrium). ...Even though the study provides a relatively large dataset, it is possible …
Genotyping of the Glu23Lys in a cohort of T1D subjects was done using the TaqMan allelic discrimination assay (frequency of the Lys-a …
Unusual neurological manifestation of severe digitoxin intoxication with bilateral ballism and visual hallucinations.
Holstein A, Hassan A, Patzer OM, Rohde M. Holstein A, et al. Aging Clin Exp Res. 2015 Jun;27(3):391-3. doi: 10.1007/s40520-014-0289-9. Epub 2014 Nov 13. Aging Clin Exp Res. 2015. PMID: 25391368 No abstract available.
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
Holstein A, Kovacs P, Beil W. Holstein A, et al. Curr Drug Saf. 2013 Apr;8(2):148-52. doi: 10.2174/15748863113089990027. Curr Drug Saf. 2013. PMID: 23845193
A 70-year old Caucasian male with liver cirrhosis Child-Pugh A, advanced hepatocellular carcinoma and diabetes had a stable glycemic control being treated with glibenclamide (3.5 mg twice daily). After the first daily dose of the TKI sorafenib (800 mg) the pa
A 70-year old Caucasian male with liver cirrhosis Child-Pugh A, advanced hepatocellular carcinoma and diabetes had a st
CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Holstein A, Beil W, Kovacs P. Holstein A, et al. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1549-63. doi: 10.1517/17425255.2012.722619. Expert Opin Drug Metab Toxicol. 2012. PMID: 23153186 Review.
Compared to wild-type carriers, patients treated with TZDs and carrying the common CYP2C8*3 and *4 variants showed a reduced glycaemic control. ...
Compared to wild-type carriers, patients treated with TZDs and carrying the common CYP2C8*3 and *4 variants showed a reduced glycaemi …
258 results
Jump to page
Feedback